22.418 articles found

METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROLOGICAL DISORDERS

LANGSTON WILLIAM J.

· 2008-06-26

Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function.

Perez XA, Bordia T, McIntosh JM, Grady SR, Quik M.

Mol Pharmacol · 2008-06-26

DOI: 10.1124/mol.108.048843PMID: 18583454

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, Parkinson's Disease Research Group of the United Kingdom.

Neurology · 2008-06-25

DOI: 10.1212/01.wnl.0000310812.43352.66PMID: 18579806

Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition.

Rowe JB, Hughes L, Ghosh BC, Eckstein D, Williams-Gray CH, Fallon S, Barker RA, Owen AM.

Brain · 2008-06-24

DOI: 10.1093/brain/awn112PMID: 18577547

Mechanism and treatment of dropped head syndrome associated with parkinsonism.

Oyama G, Hayashi A, Mizuno Y, Hattori N.

Parkinsonism Relat Disord · 2008-06-24

DOI: 10.1016/j.parkreldis.2008.04.040PMID: 18573677

The treatment of Parkinson's disease with dopamine agonists.

Konta B, Frank W.

GMS Health Technol Assess · 2008-06-18

PMID: 21289911

Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.

Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM.

J Clin Endocrinol Metab · 2008-06-17

DOI: 10.1210/jc.2007-2658PMID: 18559921

Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.

Dupuy D, Lesbre JP, Gérard P, Andrejak M, Godefroy O.

J Neurol · 2008-06-16

DOI: 10.1007/s00415-008-0839-1PMID: 18560792

Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease.

Scigliano G, Ronchetti G, Girotti F, Musicco M.

Parkinsonism Relat Disord · 2008-06-16

DOI: 10.1016/j.parkreldis.2008.04.036PMID: 18556236

A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.

Rao N, Dvorchik B, Sussman N, Wang H, Yamamoto K, Mori A, Uchimura T, Chaikin P.

J Clin Pharmacol · 2008-06-13

DOI: 10.1177/0091270008320924PMID: 18552277

Acute dehydroepiandrosterone treatment exerts different effects on dopamine and serotonin turnover ratios in the rat corpus striatum and nucleus accumbens.

Pérez-Neri I, Méndez-Sánchez I, Montes S, Ríos C.

Prog Neuropsychopharmacol Biol Psychiatry · 2008-06-10

DOI: 10.1016/j.pnpbp.2008.06.002PMID: 18585426

6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.

Rangel-Barajas C, Silva I, García-Ramírez M, Sánchez-Lemus E, Floran L, Aceves J, Erlij D, Florán B.

Neuropharmacology · 2008-06-07

DOI: 10.1016/j.neuropharm.2008.06.002PMID: 18588904